LRMR Stock Price | Larimar Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Larimar Therapeutics Inc • LRMR

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Larimar Therapeutics Inc

Ticker

LRMR

Trading on

NASDAQ

ISIN

US5171251003

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Carole S. Ben-Maimon M.D.

Headquarters

Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004

Employees

Website

https://larimartx.com

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Metrics

BasicAdvanced

Market cap

$297M

P/E ratio

EPS

-$1.96

Dividend Yield

0.00%

Beta

1.05

Forward P/E ratio

EBIDTA

$-139M

Ex dividend date

Price & volume

Market cap

$297M

Average daily volume

1.6M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

2.14

Earnings

EPS

-$1.96

EPS estimate (current quarter)

-$0.42

EPS estimate (next quarter)

-$0.42

EBITDA

$-139M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.05

52-week High

$6.91

52-week Low

$1.61

50-day moving average

$3.97

200-day moving average

$3.19

Short ratio

6.17

Short %

17.70%

Management effectiveness

ROE (TTM)

-78.24%

ROA (TTM)

-42.99%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

85.6M

Float

37.3M

Insiders %

1.07%

Institutions %

100.12%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 11 analysts.

Average price target

$16.70

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.45

-$0.32

-40.89%

Q4 • 24Missed

-$0.46

-$0.41

-12.44%

Q1 • 25Missed

-$0.41

-$0.48

14.64%

Q2 • 25Beat

-$0.61

-$0.41

-47.77%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-26.2M

-∞%

Q2 • 25

$0M

$-47.7M

-∞%

Q3 • 25

NaN%

82.23%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$150M

$30.1M

20.09%

Q2 • 25

$187M

$48.3M

25.79%

Q3 • 25

24.91%

60.32%

28.35%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-19.4M

$18.8M

$0M

$-19.4M

Q2 • 25

$-28.8M

$33M

$65.3M

$-28.8M

Q3 • 25

48.36%

75.24%

∞%

48.33%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Larimar Therapeutics Inc share?

Larimar Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Larimar Therapeutics Inc have?

Larimar Therapeutics Inc currently has 85.6M shares.

Does Larimar Therapeutics Inc pay dividends?

No, Larimar Therapeutics Inc doesn't pay dividends.

What is Larimar Therapeutics Inc 52 week high?

Larimar Therapeutics Inc 52 week high is $6.91.

What is Larimar Therapeutics Inc 52 week low?

Larimar Therapeutics Inc 52 week low is $1.61.

What is the 200-day moving average of Larimar Therapeutics Inc?

Larimar Therapeutics Inc 200-day moving average is $3.19.

Who is Larimar Therapeutics Inc CEO?

The CEO of Larimar Therapeutics Inc is Dr. Carole S. Ben-Maimon M.D..

How many employees Larimar Therapeutics Inc has?

Larimar Therapeutics Inc has 65 employees.

What is the market cap of Larimar Therapeutics Inc?

The market cap of Larimar Therapeutics Inc is $297M.

What is the P/E of Larimar Therapeutics Inc?

The current P/E of Larimar Therapeutics Inc is null.

What is the EPS of Larimar Therapeutics Inc?

The EPS of Larimar Therapeutics Inc is -$1.96.

What is the PEG Ratio of Larimar Therapeutics Inc?

The PEG Ratio of Larimar Therapeutics Inc is null.

What do analysts say about Larimar Therapeutics Inc?

According to the analysts Larimar Therapeutics Inc is considered a buy.